Australia's Kazia rises on U.S., India patents for brain tumour inhibitor

Kazia Therapeutics

24/06/2021 04:39

** Oncology-focused drug maker Kazia Therapeutics Ltd
 KZA.AX  gains as much as 3.5% to A$1.345
    ** Co says it was granted patents by agencies in the United
States and India for manufacturing process of paxalisib, an
inhibitor used to treat brain tumours  urn:newsml:reuters.com:*:nASN001D7F
    ** KZA says a similar patent has been accepted in Australia
and is expected to proceed to grant in 3Q CY2021
    ** Stock posts its biggest intraday gain since June 15
    ** KZA up 12.1% this year, as of last close
       

 (Reporting by Aditya Munjuluru in Bengaluru)
 ((aditya.srivastsav@thomsonreuters.com))